Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
or

Artara Therapeutics Inc (TARA)

Artara Therapeutics Inc (TARA)
4.15 x 5 4.24 x 1
Post-market by (Cboe BZX)
4.20 +0.26 (+6.60%) 04/23/25 [NASDAQ]
4.15 x 5 4.24 x 1
Post-market 4.20 unch (unch) 16:01 ET
Quote Overview for Wed, Apr 23rd, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
4.09
Day High
4.59
Open 4.09
Previous Close 3.94 3.94
Volume 601,941 601,941
Avg Vol 350,027 350,027
Stochastic %K 44.98% 44.98%
Weighted Alpha -12.57 -12.57
5-Day Change +0.03 (+0.72%) +0.03 (+0.72%)
52-Week Range 1.60 - 10.48 1.60 - 10.48
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 144,862
  • Shares Outstanding, K 36,767
  • Annual Sales, $ 0 K
  • Annual Income, $ -44,600 K
  • EBIT $ -49 M
  • EBITDA $ -50 M
  • 60-Month Beta 1.60
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.81

Options Overview Details

View History
  • Implied Volatility 235.79% ( +38.74%)
  • Historical Volatility 73.17%
  • IV Percentile 91%
  • IV Rank 39.96%
  • IV High 559.87% on 11/20/24
  • IV Low 20.12% on 09/17/24
  • Put/Call Vol Ratio 0.12
  • Today's Volume 1,095
  • Volume Avg (30-Day) 389
  • Put/Call OI Ratio 0.34
  • Today's Open Interest 5,737
  • Open Int (30-Day) 7,497

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.47
  • Number of Estimates 3
  • High Estimate -0.37
  • Low Estimate -0.53
  • Prior Year -0.97
  • Growth Rate Est. (year over year) +51.55%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.54 +18.64%
on 04/09/25
Period Open: 4.60
4.81 -12.76%
on 03/25/25
-0.40 (-8.70%)
since 03/21/25
3-Month
3.19 +31.66%
on 03/04/25
Period Open: 4.71
5.26 -20.15%
on 02/04/25
-0.51 (-10.83%)
since 01/23/25
52-Week
1.60 +163.32%
on 10/10/24
Period Open: 3.00
10.48 -59.92%
on 12/05/24
+1.20 (+40.00%)
since 04/23/24

Most Recent Stories

More News
Protara Therapeutics to Host Conference Call and Webcast to Review Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC on Monday, April 28, 2025

TARA : 4.20 (+6.60%)
Protara Therapeutics Announces Appointment of Leonardo Viana Nicacio, M.D., as Chief Medical Officer

TARA : 4.20 (+6.60%)
Protara Therapeutics to Present Interim Analysis from the Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC at the American Urological Association Annual Meeting

TARA : 4.20 (+6.60%)
Protara Therapeutics Announces Encore Presentation of Results from THRIVE-1 Prospective Observational Study Evaluating the Prevalence of Choline Deficiency and Liver Injury in Patients Dependent on Parenteral Support

TARA : 4.20 (+6.60%)
From Clinical Trials to the Market: Cancer Stocks With Big Potential in 2025

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – USA News Group News Commentary – As cancer rates continue to climb worldwide, the push for innovative treatments has never been more...

ALLO : 1.6100 (+1.26%)
ONCY : 0.5666 (-5.57%)
TARA : 4.20 (+6.60%)
YMAB : 4.12 (-3.29%)
FATE : 1.3300 (-2.92%)
ONC.TO : 0.79 (-5.95%)
Protara Therapeutics: Q4 Earnings Snapshot

Protara Therapeutics: Q4 Earnings Snapshot

TARA : 4.20 (+6.60%)
Protara Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

TARA : 4.20 (+6.60%)
Protara Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference

TARA : 4.20 (+6.60%)
Protara Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

TARA : 4.20 (+6.60%)
Protara Highlights Recent Updates and Anticipated 2025 Milestones

TARA : 4.20 (+6.60%)

Business Summary

Protara Therapeutics Inc. is committed to identifying and advancing transformative therapies for rare and specialty diseases. The company's portfolio includes, TARA-002, an investigational cell therapy being developed for the treatment of lymphatic malformations, and intravenous Choline Chloride, an...

See More

Key Turning Points

3rd Resistance Point 4.37
2nd Resistance Point 4.22
1st Resistance Point 4.08
Last Price 4.20
1st Support Level 3.79
2nd Support Level 3.64
3rd Support Level 3.50

See More

52-Week High 10.48
Fibonacci 61.8% 7.09
Fibonacci 50% 6.04
Fibonacci 38.2% 4.99
Last Price 4.20
52-Week Low 1.60

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Value Investing Philosophies: Graham, Buffett, Bogle, and EMH in Perspective